

# Dorothea M Peters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/703112/publications.pdf>

Version: 2024-02-01

50  
papers

2,615  
citations

236925

25  
h-index

197818

49  
g-index

50  
all docs

50  
docs citations

50  
times ranked

3286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. <i>Brain</i> , 2019, 142, 744-759.	7.6	636
2	Short-term effects of coenzyme Q <sub>10</sub> in progressive supranuclear palsy: A randomized, placebo-controlled trial. <i>Movement Disorders</i> , 2008, 23, 942-949.	3.9	135
3	The spectrum of $\alpha$ -syn in Parkinson's disease: What have we learned over 40 years?. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 9-16.	2.2	115
4	High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 822-832.	3.7	114
5	Mitochondrial damage by $\alpha$ -synuclein causes cell death in human dopaminergic neurons. <i>Cell Death and Disease</i> , 2019, 10, 865.	6.3	112
6	Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson's Disease. <i>Pharmacoeconomics</i> , 2001, 19, 1013-1038.	3.3	105
7	Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. <i>Sleep Medicine</i> , 2008, 9, 228-239.	1.6	105
8	Recent advances in treating Parkinson's disease. <i>F1000Research</i> , 2017, 6, 260.	1.6	92
9	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1437-1444.	5.0	80
10	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
11	Costs of drug treatment in Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 249-254.	3.9	74
12	Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome. <i>Movement Disorders</i> , 1998, 13, 820-824.	3.9	69
13	Treatment of Idiopathic Restless Legs Syndrome (RLS) with the D2-agonist Cabergoline – An Open Clinical Trial. <i>Sleep</i> , 2000, 23, 1-6.	1.1	67
14	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> , 2017, 32, 1482-1486.	3.9	67
15	Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. <i>Scientific Reports</i> , 2017, 7, 11469.	3.3	52
16	Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. <i>Movement Disorders</i> , 2003, 18, 430-432.	3.9	49
17	Trifluoperazine rescues human dopaminergic cells from wild-type $\alpha$ -synuclein-induced toxicity. <i>Neurobiology of Aging</i> , 2014, 35, 1700-1711.	3.1	48
18	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 224-229.	3.9	47

#	ARTICLE	IF	CITATIONS
19	Widespread microglial activation in multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 564-568.	3.9	41
20	Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. <i>Experimental Neurology</i> , 2014, 253, 113-125.	4.1	39
21	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. <i>BMJ Open</i> , 2014, 4, e005122-e005122.	1.9	35
22	Calcium-activated SK potassium channels are key modulators of the pacemaker frequency in locus coeruleus neurons. <i>Molecular and Cellular Neurosciences</i> , 2018, 88, 330-341.	2.2	35
23	Four-Year Follow-up of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression. <i>Movement Disorders</i> , 2021, 36, 230-235.	3.9	31
24	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747.	3.9	29
25	Risk Factors for Phenocconversion in Rapid Eye Movement Sleep Behavior Disorder. <i>Annals of Neurology</i> , 2022, 91, 404-416.	5.3	27
26	DTI and VBM reveal white matter changes without associated gray matter changes in patients with idiopathic restless legs syndrome. <i>Brain and Behavior</i> , 2015, 5, e00327.	2.2	26
27	Chronic consumption of <i>Annona muricata</i> juice triggers and aggravates cerebral tau phosphorylation in wild-type and <i>MAPT</i> transgenic mice. <i>Journal of Neurochemistry</i> , 2016, 139, 624-639.	3.9	26
28	Validation of a new data-driven automated algorithm for muscular activity detection in REM sleep behavior disorder. <i>Journal of Neuroscience Methods</i> , 2019, 312, 53-64.	2.5	23
29	Autonomic Seizures Versus Syncope in 18q- Deletion Syndrome: A Case Report. <i>Epilepsia</i> , 2000, 41, 1039-1043.	5.1	22
30	Mutant $\alpha$ -Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 47-57.	3.6	22
31	Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 749-753.	3.9	21
32	Selegiline normalizes, while L-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2014, 79, 212-221.	4.1	21
33	Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease. <i>Molecular Medicine</i> , 2021, 27, 111.	4.4	20
34	Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). <i>Journal of Nuclear Medicine</i> , 2014, 55, 1281-1287.	5.0	19
35	Piericidin A Aggravates Tau Pathology in P301S Transgenic Mice. <i>PLoS ONE</i> , 2014, 9, e113557.	2.5	15
36	The roles of connectivity and neuronal phenotype in determining the pattern of $\alpha$ -synuclein pathology in Parkinson's disease. <i>Neurobiology of Disease</i> , 2022, 168, 105687.	4.4	14

#	ARTICLE	IF	CITATIONS
37	Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons. <i>Neuroscience</i> , 2017, 365, 137-145.	2.3	12
38	Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse. <i>Scientific Reports</i> , 2019, 9, 13359.	3.3	12
39	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 229-239.	2.8	12
40	Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension. <i>CNS Drugs</i> , 2016, 30, 749-760.	5.9	11
41	Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2022, 12, 3180.	3.3	10
42	Is increased spinal nociception another hallmark for Parkinsonâ€™s disease?. <i>Journal of Neurology</i> , 2017, 264, 570-575.	3.6	9
43	Role of dopamine transporter SPECT for the practitioner and the general neurologist. <i>Movement Disorders</i> , 2003, 18, S9-S15.	3.9	7
44	Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation. <i>Journal of Chemical Neuroanatomy</i> , 2014, 61-62, 169-175.	2.1	7
45	Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinsonâ€™s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 851788.	3.4	7
46	Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern. <i>Movement Disorders</i> , 2021, , .	3.9	6
47	Eye tracking identifies biomarkers in Î±-synucleinopathies versus progressive supranuclear palsy. <i>Journal of Neurology</i> , 2022, 269, 4920-4938.	3.6	6
48	Biceps electromyography in dialeptic and automotor seizures with and without secondary generalization. <i>Clinical Neurophysiology</i> , 2016, 127, 1163-1169.	1.5	3
49	Rasagiline. <i>Drugs and Aging</i> , 2005, 22, 93-94.	2.7	1
50	Do different assays for human acylated ghrelin concentrations provide comparable results?. <i>Neuroendocrinology Letters</i> , 2014, 35, 37-41.	0.2	0